TScan will provide a summary of the Company’s ASGCT posters and oral presentation as well as a discussion of TScan’s solid tumor programs. The virtual event will feature Key Opinion Leader (KOL) Kai Wucherpfennig, M.D., Ph.D. (Dana-Farber Cancer Institute).

TScan is leveraging its proprietary platform technologies to develop TCR-T therapies to build its ImmunoBank, the Company’s diverse bank of therapeutic TCRs, that recognize diverse targets and are associated with multiple HLA types in order to provide a broad array of therapeutic options for patients with various tumor types.

 A live question and answer session will follow.